Skip to content
Stock screener

VBIO Valion Bio, Inc. stock chart & analysis

Conviction 54HealthcareScan · Thu, Nov 19, 2026
Bullish harami

Valion Bio, Inc. (VBIO) closed at $0.5414 (+7.76%) on Nov 19, 2026. Its latest daily candle is a bullish harami. Price is below its 50-day. RSI(14) 26, -98.6% from its 52-week high, -98.2% year to date. Sector: Healthcare · Pharmaceutical Preparations.

VBIO$0.5414+7.76%
ResistanceSupportVol 14
Loading chart…

Why VBIO moved

From the StockSetups movers recaps that covered VBIO, newest first. A recap states what was known that day.

  • Premarket+41.3%

    No headlines are on file for VBIO this morning, and no explanatory press release has been identified. The most recent SEC filings include a September 1 8-K flagged as dilutive (bearish) and a series of 13D/G stake-change filings in early September, suggesting active institutional positioning around the name.

    Premarket Movers Sept 30, 2026: CNTB, LGHL, VBIO →
Valion Bio, Inc.Pharmaceutical Preparationswww.tivichealth.com ↗
Price0.5414
Change+7.76%
Gap+1.51%
Rel volume—
Avg volume1.13M
Avg $ vol880.34K
SMA 200.5863
SMA 501.50
SMA 200—
Price vs 50-63.94%
Price vs 200—
MA stack—
50/200 cross—
Supertrenddown · 0.8044
RSI (14)26
MACD hist0.09
MACD cross—
Stoch %K / %D55 / 37
ADX (14)13
+DI / −DI24 / 25
RSI divergence—
MACD divergence—
ATR %28.29%
ADR %11.75%
52w high39.00
52w low0.4715
From 52w high-98.61%
Above 52w low+14.83%
New 52w highNo
SqueezeOn · 2d
Bollinger width83.30%
%B0.41
Donchian pos14.43%
Donchian high0.9558
Donchian low0.4715
AVWAP (52w high)3.26
vs AVWAP high-83.39%
AVWAP (52w low)0.5306
vs AVWAP low+2.04%
OBV trendDown
Chaikin MF (20)0.41
Today vs 20d—
Avg vol (14d)281.51K
Avg vol (20d)1.13M
Avg $ vol (20d)880.34K
Market cap12.01M
RS Rating—
RS 3m (vs SPY)-78.77%
RS 6m (vs SPY)-94.33%
RS line new highNo
Trend template—
Technical rank9.2
1 week+6.45%
1 month-51.66%
3 months-85.28%
6 months-97.95%
1 year—
YTD-98.21%
P/E-1.35
P/B2.83
P/S—
P/FCF-1.71
EPS-7.84
Div yield—
ROE-209.09%
ROA-27.34%
Debt/Eq—
Current1.11
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth-56.99%
Price target—
Target upside—
Analyst rating—
Institutional1.79%
Ent. value9.91M
Revenue—
Net income-7.1M
Gross profit—
Free cash flow-7.04M
IndustryPharmaceutical Preparations
ExchangeNasdaq
Shares out3.2M
Employees52
ListedThu, Nov 11, 2021
Free float3.09M
Float %98.5%
Short interest—
Days to cover—
Short volume45.6%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction54 / 100
Pattern quality—
Tech rank9.2 / 100
Group rank—
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmBullish harami

Financials as of Tue, Jun 30, 2026 · quarterly.

VBIO technical analysis

Trend

It closed 63.9% below the 50-day ($1.50). ADX(14) at 13 points to a weak trend — more range than direction.

Momentum

RSI(14) is 26, in oversold territory. The MACD histogram is positive.

Volume and volatility

It trades about $880,344 a day on average. ATR(14) is $0.1532, 28.3% of price — its typical daily range. Bollinger Bands are in a squeeze (2 sessions) — volatility is compressed. On-balance volume is trending down. Chaikin Money Flow (0.41) shows accumulation.

Key levels

The 52-week range is $0.4715 to $39.00; price is 98.6% below the high and 14.8% above the low. The VWAP anchored at the 52-week high is $3.26, above price.

Performance

VBIO returned +6.5% (1 week), -51.7% (1 month), -85.3% (3 months), -98.0% (6 months), -98.2% (year to date).

About Valion Bio, Inc.

Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.

Pharmaceutical Preparations · Listed 2021 · 52 employees

Insider activity

SEC Form 4 transactions in VBIO

InsiderSideShares
Wolf Lisa G
Chief Financial Officer · Restricted Stock Units · 2026-06-18
Exercise92
Wolf Lisa G
Chief Financial Officer · Common Stock · 2026-06-18
Exercise92
Handley Michael K
Chief Executive Officer · Common Stock · 2026-05-18
Exercise2.21K
Handley Michael K
Chief Executive Officer · Restricted Stock Units · 2026-05-18
Exercise2.21K
Lackey Melinda
General Counsel & SVP of Legal · Employee Stock Option (Right to Purchase) · 2026-05-01
Grant45K

SEC filings

EDGAR filings in VBIO · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.